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Opinion statement
Colorectal cancer (CRC) forms an important public health problem, especially in developed
countries. CRC screening tests can be used to identify asymptomatic individuals with CRC
precursors and (early) cancer. Removal of these lesions reduces CRC incidence and
prevents CRC-related mortality. There are a range of screening tests available, each with
advantages and disadvantages. Stool screening tests can broadly be divided into fecal
occult blood tests (FOBTs) and molecular biomarker test, such as DNA/RNA marker tests,
protein markers, and fecal microbiome marker tests. Guaiac fecal occult blood tests
(gFOBT) have been demonstrated in large randomized screening trials to reduce CRC
mortality. Fecal immunochemical tests (FIT) have superior adherence, usability, and
accuracy as compared to gFOBT. Advantage of the use of quantitative FITs in CRC screening
programs is the cut-off level that can be adjusted. Molecular biomarker DNA tests have
shown to detect significantly more cancers than FIT. By combining biomarker DNA tests
with FIT, sensitivity for advanced adenomas can be increased significantly. However, it has
lower specificity thus demands more colonoscopy resources, is more cumbersome, and
costly. The adherence has not been assessed in population screening trials. For these
reasons, FIT is therefore at present regarded as the preferred method of non-invasive CRC
screening. This chapter will review the current status of fecal test-based CRC screening.
Introduction
Colorectal cancer (CRC) forms an important public
health problem, especially in developed countries [1].
It ranks third among the most commonly diagnosed
cancers worldwide, affecting approximately 1.23million
patients each year [2]. In developed countries, it is the
second cause of cancer-related death in men and the
third cause in women [3, 4]. The high incidence and
associated mortality, and the natural history of CRC
with slow progression from a premalignant polyp to
cancer, makes CRC very suitable for population screen-
ing [5, 6]. The National Polyp Study within the USA
showed that adenoma removal reduced the incidence
of CRC by 76–90 %. After a median follow-up of nearly
16 years, colonoscopy with removal of adenomas result-
ed in a 53% reduction in CRCmortality (mortality ratio
0.47, 95 % CI 0.26–0.80) compared to the expected
CRC mortality rate in the general population [7, 8].
Further studies showed that screening and prevention
of CRC is cost-effective and dependent on strategy also
cost-saving [9].
Various CRC screening tests are available, which can
basically be divided into non-invasive stool or blood
tests and more invasive imaging or endoscopy proce-
dures. There is no single worldwide-agreed optimal CRC
screeningmethod. This results in different approaches in
various countries [10•]. The choice which screening
method should be used is mainly dependent on finan-
cial and endoscopy resources, and secondly on the will-
ingness of the population to undergo the primary
screening test. As a result of limited resources and pop-
ulation preferences for non-invasive screening, many
organized screening programs use a two-step approach.
This includes primary screening with a non-invasive
fecal test, followed by bowel inspection by means of
colonoscopy for individuals that tested positive. For a
screening test, several test characteristics are necessary.
Since screening involves asymptomatic and mostly
healthy people, a test should be safe, meaning that the
test and screening program should cause no harm. In
this light, a high test-specificity is preferred, reducing the
risks of harm from both unnecessary (follow-up) testing
and overdiagnosis. This is contrary to a diagnostic test in
a clinical setting, where the high pretest-probability of
the disease has often already been established and the
disease needs to be confirmed or ruled out. Further-
more, a screening test should be acceptable to the
screenee. Adherence rates of those invited for screen-
ing are a direct reflection of the acceptance of the
test. A screening program with low adherence will by
definition not impact on CRC incidence and mortal-
ity, irrespective of the characteristics of the test that is
offered. Also, practical use and costs of the test need
to be taken into account. Fecal tests may differ in
positivity rate, and thus the number of people re-
ferred for colonoscopy. They consequently have dif-
ferent demands for colonoscopy resources. Recently,
the variability of fecal tests as CRC screening tool is
rapidly increasing, and more countries have been
implementing CRC screening programs. The large
variability and expanding range of fecal tests may
impair knowledge of the available screening options.
Therefore, this review aims to give an overview of the
recent advances in fecal tests and its use in colorectal
cancer screening programs.
Fecal occult blood tests
Fecal occult blood tests (FOBTs) detect hemoglobin (Hb) in feces. A range of
FOBTs is available; they can be divided into two types: guaiac FOBT (gFOBT)
and fecal immunochemical tests (FIT).
Guaiac fecal occult blood tests
Guaiac tests were already available a century ago. They were then used to detect
gastric blood loss from peptic ulcer and gastric cancer, conditions that affected
large numbers of patients. Guaiac FOBTs were in the 1970s the first widely used
FOBT for population-based CRC screening. The gFOBT detects blood by the use
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of guaiac-impregnated paper to which hydro-peroxidase is added. In contact
with heme, the hydro-peroxidase oxygenizes guaiac leading to a blue discolor-
ation. The test result, i.e., the blue discoloration, is qualitative (positive/nega-
tive). The standard gFOBT consists of three paper cards each with two panels,
requiring sampling from three separate stools. Guaiac FOBTs can be analyzed
with and without hydration. The former has the advantage of a higher sensi-
tivity; however, it also leads to more false-positives [11]. The impact of gFOBT
screening on CRC incidence and mortality has been prospectively assessed in
several, large randomized trials. These trials demonstrated that repeated annual
or biennial gFOBT screening reduces CRC-related mortality by approximately
32–33 and 6–18 %, respectively [12–15]. The Minnesota trial, which used
rehydrated gFOBT, also demonstrated a reduction in CRC incidence [14]. A
subsequent meta-analysis reported a pooled 15 % reduction in CRC-related
death among the three biennial screening trials with gFOBT compared to
controls [16]. The Minnesota trial recently after 30 years follow-up reported an
overall 27 % reduction in CRC mortality [17].
A main disadvantage of gFOBT is that it does not specifically target human
heme. Hydro-peroxidase also reacts with non-human heme present in redmeat.
This may cause a false-positive test result. Several fresh fruits and vegetables
contain peroxidase activity, which may also lead to false-positive test results.
Vitamin Cmay on the contrary block the peroxidase reaction, resulting in false-
negative test results [18]. As a result of the dietary restrictions and the need for
three different samples on consecutive days, adherence rates of gFOBT screening
are generally poor [18, 19]. Furthermore, although gFOBT has a high specificity,
its sensitivity is limited since it does not detect hemoglobin concentrations
below approximately 600 μg/g feces [11]. Consequently, adenomatous polyps,
precursors of most CRCs, are less likely to be detected as they generally bleed
less. The focus on early cancers provides a short window of opportunity, which
explains the need for short screening intervals. For these reasons, high sensitivity
gFOBTs have been designed, with an enhancer to allow detection of lower Hb
concentrations [20]. However, these gFOBTs come with a lower specificity
making these test less suitable for population-based screening. Due to the low
sensitivity and adherence rates, gFOBT screening is associated with a significant
proportion of interval cancers [19]. In the Scottish population program, the
proportion of interval cancers increased from 31.2 to 58.9 % after the first,
respectively, third screening round [21•]. This increase can partly be explained
by a decrease in screen-detected cancers over the screening rounds.
Fecal immunochemical tests for hemoglobin
Fecal immunochemical tests detect human globin by means of an
antibody-based assay. FITs either provide a qualitative result or quantita-
tive result in terms of fecal Hb concentration per gram feces. The latter has
the advantage that the selection of cut-off level in population-based
screening can be tailored to financial and endoscopy resources. There are
many different FIT brands available on the market. Figure 1 shows some of
the different FITs. These tests sample different amounts of fecal material,
use different amounts of buffers, analytical procedures, and reporting
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units. They generally present results as Hb concentration in nanograms per
milliliter test buffer. As a result of these differences, the quantitative results
of different tests cannot be compared one-to-one. It has therefore been
proposed to standardize the reporting units of fecal Hb to microgram Hb
per gram feces [22]. However, even when using these standardized Hb
concentrations, different brand of FITs perform differently in mass
screening [23]. These differences apply for both qualitative and quantita-
tive results [18]. Currently, there is no evidence for one FIT to be superior
over another [19].
At present, there are no results from large prospective randomized trials
concerning the impact of repeated FIT screening on CRC incidence and
mortality. Even so, the current European guidelines recommend FIT
screening as the preferred method of fecal occult blood testing [24, 25].
Screening by means of FIT has advantages over gFOBT screening (Table 1).
Firstly, FIT testing requires only one stool sample instead of sampling from
three bowel movements. Furthermore, the sampling probe connected to
the inside of the lid of the test facilitates test handling (Fig. 1). Together,
this results in significantly higher adherence rates with higher detection
Fig. 1. FIT brands with different sampling probes, collection tubes, and volume of preservative buffer.
Table 1. Differences between gFOBT and FIT screening in average-risk individuals
gFOBT FIT
Repeat sampling from multiple bowel movements Single sampling from one bowel movement
Dietary restrictions No dietary restrictions
Qualitative result Quantitative or qualitative result
Semi-automated analysis Automated analysis
Sensitivity CRC 31 – 63 %a Sensitivity CRC 69 – 100 %b
Specificity CRC 92 – 96 %a Specificity CRC 92 – 96 %b
a[26, 27]
b[28–30]
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rates of CRC and advanced adenomas [31]. Also, FIT is more sensitive in
detecting hemoglobin than gFOBT with reported sensitivities for advanced
neoplasia detection of two to three times higher compared to gFOBT [32].
This higher sensitivity for advanced neoplasia would allow prevention of
the development of CRC, and thereby potentially decreasing CRC inci-
dence in addition to detecting CRC in an early stage. Lastly, when com-
paring FIT to gFOBT regarding cost-effectiveness, FIT screening is more
cost-effective at any given cut-off. At the same colonoscopy demand, FIT
screening led to lower costs and more life years gained than gFOBT [33].
FIT performance shows variability among different subgroups. Some
studies reported a higher sensitivity for left-sided adenomas than right-
sided lesions [28, 34]. Also, FIT sensitivity has shown to be higher for
aspirin users compared with nonusers [35]. At the same cutoff, men have
higher FIT positivity rates than women [36]. This is a reflection of the
higher prevalence of advanced neoplasia in men, as well as their more
frequent distal location [37].
Currently,most quantitative FITs have beenmainly usedwith a fixed cut-off,
thereby limiting the FIT to a qualitative result (i.e., either positive or negative).
Rationale for choosing a specific cut-off greatly depends on the aim of screening
and available colonoscopy resources [33]. Using a higher cut-off is of particular
interest in situations with limited colonoscopy capacity where screening pro-
grams aim for maximal diagnostic yield with restricted resources [38]. A high
cut-off also comeswith a high positive predictive value. A lower cut-off increases
sensitivity for detection of subjects with advanced neoplasia but requires larger
colonoscopy resources due to a lower positive predictive value. There is still
much to gain concerning the quantitative nature of FIT, as the exact fecal Hb
concentration could be of great clinical use. There is evidence that fecal Hb
concentration is related to the severity of advanced neoplasia [39]. By adding
fecal Hb concentration in predictivemodels, individuals with the highest risk of
advanced neoplasia can be identified [40]. This may also allow for gender-
specific approaches. Combining individual fecal Hb concentrations with other
risk factors for CRC to base colonoscopy indication on, and not solely a
qualitative test result, could possibly improve FIT-screening efficiency. Also, FIT
could be of clinical importance after the initial positive test result, because the
fecal Hb concentration is associated with the risk of a second colonoscopy
within 1 year after screening colonoscopy [41]. Future research in FIT screening
should therefore explore the possibilities of incorporating individual fecal Hb
levels in CRC screening programs.
DNA- and RNA-based biomarker tests
DNA- and RNA-based stool tests aim to detect markers of aberrant DNA or
RNA from neoplastic cells. They are based on the principle that colorectal
neoplasms shed surface cells in stool. DNA or RNA from these cells can be
isolated and tested for the presence of mutations and epigenetic changes
acquired during carcinogenesis. DNA- and RNA-based testing is relatively
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new compared to FOBTs. DNA analysis techniques are developing rapidly
and are very sensitive [42].
DNA markers
A recent study combined FIT with several DNAmarkers, consisting ofmolecular
assays for aberrantly methylated BMP3 and NDRG4 promoter regions, mutant
KRAS, and β-actin (a reference gene for human DNA quantity) [43••]. This
multi-target stool DNA plus FIT test had a significantly higher sensitivity for
advanced adenomas (42 %) and a somewhat higher sensitivity for CRC (92 %)
than FIT alone (sensitivity for advanced adenoma 23 %, for CRC 72 %).
However, this increase in detection came against the background of a consid-
erably higher test positivity rate (16 vs. 7 %). As a consequence, the demand for
colonoscopy is more than twice as high after DNA-FIT testing than after FIT
alone, and the DNA-FIT test had a lower specificity for advanced neoplasia
compared to FIT, 87 versus 95 %, respectively. In the light of population-based
screening and limited colonoscopy resources, the higher positivity rate and
lower specificity are important pullbacks. Since colonoscopy resources are in
many regions the limiting factor in population screening, it has been advocated
to compare non-invasive tests not at a fixed test cut-off, but over a range of
positivity rates, allowing a direct comparison between tests at the same posi-
tivity rate [19]. Also, the multi-target DNA test requires a full stool sample to be
sent in a container, which comes with additional costs and impracticality to an
already expensive testing procedure. Furthermore, the multi-target DNA test is
recommended once every 3 years, whereas FIT is offered annually in the USA.
Cumulative sensitivity, specificity, and costs after 3 years of annual FIT screening
would therefore be the fairest comparison before drawing conclusions on
superiority of either of the two tests. Lastly, adherence to the multi-target stool
DNA test has not yet been investigated. Since adherence is crucial in screening
efficacy, this should be evaluated before proceeding to implementation of the
test in a screening program.
The performance of DNA tests may differ per CRC subtype, on the grounds
that CRC is a heterogeneous disease that can develop via multiple pathways. To
detect all CRC subtypeswith a screening test, different tumormarkers have to be
used [44, 45]. A recent study showed that different subtypes are associated with
marked differences in survival. Subjects with tumormarkers reflecting a serrated
morphology have the highest disease-specific mortality (hazard ratio 2.20)
[46]. This was compared to subjects with tumor markers reflecting the tradi-
tional adenoma-carcinoma sequence (the most predominant tumor). Howev-
er, the biologic basis for the observed difference remains an important topic for
future research.
RNA markers
A microRNA (miRNA) is a small non-coding RNA molecule (containing
approximately 22 nucleotides), which functions in RNA silencing and
post-transcriptional regulation of gene expression. MiRNAs are thought to
be cell-type and disease-specific and may be quantified in stool by quan-
titative real-time polymerase chain reaction (qPCR) [47]. Aberrant
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expression of a specific miRNA may display the effects of a tumor sup-
pressor or oncogene. A large number of studies of single or panels of
miRNAs for the detection of CRC have been published recently [48]. A
Japanese group showed that the addition of fecal miRNA-106a to FIT
testing improved the sensitivity but decreased the specificity of FIT [49].
Since most published studies were based on selected populations, further
research in an asymptomatic population should be conducted.
Protein markers
Protein-based stool markers focus on either the detection of cancer-specific
proteins or detection of proteins released from inflamed and/or bleeding
tissue. Fecal tumor M2 pyruvate kinase (M2-PK) has received the most
attention as a potential cancer-specific protein marker. The test is based on
the detection of proteins in stool derived from neoplastic colonocytes. A
recently reported meta-analysis of studies comparing M2-PK with colo-
noscopy reported a pooled CRC sensitivity and specificity of 79 and 80 %,
respectively [50].
A non-cancer-specific protein marker is calprotectin. Calprotectin is a
calcium-binding protein in granulocytes, macrophages, and epithelial cells.
Elevation of calprotectin occurs during intestinal inflammation, including
inflammation caused by inflammatory bowel disease. Elevated fecal
calprotectin in CRC is suggested to be due to neutrophil shedding from an
ulcerated tumor into the intestinal lumen. A large Norwegian CRC
screening trial evaluated calprotectin and reported a lower sensitivity and
specificity than FIT [51].
So far, no single protein stool marker has shown to be of adequate
accuracy to be considered for population-based CRC screening. A Chinese
study investigated the possibility of combining seven biomarkers in a
biochip for the detection of colorectal cancer [52]. The most optimal result
was the combination of two biomarkers (TPO, FGF-23) leading to a
sensitivity of 0.8 with a specificity of 0.7 for detection of cancer. The use of
protein makers in CRC screening, or combining protein markers with FIT,
requires further research.
Currently, novel molecular tests to analyze stool for a combination of
genetic, epigenetic, and protein biomarkers are being developed. The
largest is the Molecular Early Detection of Colorectal Cancer (MEDOCC)
project. It is a long-term collaborative research between the Netherlands
and USA.
Human fecal microbiome-based biomarkers
Recent studies suggest an important role for the gut microbiome in the
development of CRC. Patients with CRC have a different gut microbiome
than healthy subjects [53]. One of the first bacteria more commonly
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found in patients with CRC was Streptococcus bovis [54]. At present, other
bacteria have been identified that play a role in gastro-intestinal cancers,
such as Helicobacter pylori, and Fusobacterium nucleatum [53]. The latter has
been of particular interest in colorectal neoplasia, with several studies
indicating that F. nucleatum in feces is associated with the occurrence of
colorectal adenomas and cancer. However, its precise role in this process
is poorly understood [53]. It has been suggested that F. nucleatum could
be useful in detecting serrated polyps [55]. This is relevant as FOBT does
not seem sensitive to serrated lesions [56]. The fecal microbiome in CRC
screening has largely been unstudied, but measuring the fecal
microbiome to identify those at risk of CRC seems promising as a novel
screening method. A major advantage of this method of screening could
be that non-bleeding lesions are also detected. One study combined the
gut microbiome with other risk factors and found that by adding the
microbiome, the pretest to posttest probability increased, resulting in
better identification of subjects with advanced neoplasia [57]. The use of
the gut microbiome as a CRC screening tool has great potential. Hence,
studies identifying specific microbiota that are associated with CRC are
much awaited.
Conclusion
There is a wide range of fecal tests for colorectal cancer screening
available. The guaiac FOBT was one of the first fecal tests used in
colorectal cancer screening. Large trials have shown a significant reduc-
tion in CRC-related mortality after screening with gFOBT. However, its
use has several limitations when compared to FIT. These limitations
include ease of use, adherence, and sensitivity. Also, FIT has the ad-
vantage that fecal Hb concentrations can be measured yielding a quan-
titative test result. Nonetheless, at present, FIT is mostly analyzed using
a pre-determined cut-off. Aside from FOBTs, to date, only DNA-based
stool tests have undergone the full spectrum of development and testing
for clinical practice. The multi-target stool DNA test was approved by
the FDA in the USA for CRC screening in 2014. So far, biomarker tests
such as the multi-target stool DNA test are more expensive than the
FOBTs, and come with a relatively low specificity. Furthermore, adher-
ence rates have not been evaluated. Therefore, a sensitive single bio-
marker or panel of biomarker (stool) tests at affordable cost is much
awaited. Also, further identification of the gut microbiome could open
up new possibilities in CRC screening strategies. Expansion of molecular
biomarker screening tests may become imaginable in the future. At the
current stage, screening by means of FIT seems the way to go. Require-
ments in test sensitivity, specificity, and costs in order for new molec-
ular biomarker technologies to be cost-effective compared to the FIT
should be investigated. Future focus should also be on using FIT quan-
titatively and incorporating FIT results in risk prediction models to
maximize screening benefit and efficacy.
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